Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Tonix PharmaceuticalsTNX-2110
Clinical Trials (1)
Total enrollment: 9 patients across 1 trials
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Start: Jan 2022Est. completion: Sep 20229 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space